New Research Says GLP-1 Drugs Like Ozempic May Not Shrink Muscle as Much as Feared
A Washington Post analysis of 2026 research finds that GLP-1 medications like Ozempic and Wegovy may not cause disproportionate muscle loss compared to other forms of weight reduction. Experts say resistance training and adequate protein intake remain the best tools for preserving muscle while on these drugs.
New research published in May 2026 suggests that GLP-1 receptor agonists like Ozempic and Wegovy may not shrink muscle mass as severely as earlier studies indicated, according to a Washington Post analysis.
The concern about muscle loss has been one of the most common criticisms of GLP-1 medications. When people lose weight quickly, the body can break down muscle tissue for energy, a condition sometimes called sarcopenic obesity. But researchers now say the muscle loss seen in GLP-1 users may not be disproportionate compared to other methods of significant weight reduction.
The medical consensus is shifting toward a more practical view: some muscle loss is expected with any major weight reduction, and the focus should be on preservation rather than alarm.
Doctors recommend two to three sessions of resistance training per week for patients on GLP-1 therapy. Adequate protein intake is also critical. Studies from 2024 found that patients who combined GLP-1 therapy with regular exercise maintained their weight loss more effectively and experienced less weight regain after stopping the medication.
Researchers are also studying longer-term effects on bone health. Some observational data suggest potential links to osteoporosis and tendon issues, though experts say these are more likely tied to rapid weight loss and reduced physical activity than to the drugs themselves.
GLP-1 medications have shown benefits beyond weight loss, including reduced risk of heart attack, stroke, and cardiovascular death. Researchers are also studying their potential role in breast cancer survival and reducing food cravings.
